Received Sep 23, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 1 | — | LA |
she had a red injection site that was hot; she had a red injection site that was hot; Hot dry skin; This non-serious case was reported by a consumer via call center representative and described the occurrence of injection site erythema in a female patient who received Herpes zoster (Shingrix) for prophylaxis. On an unknown date, the patient received the 1st dose of Shingrix (left arm). On an unknown date, an unknown time after receiving Shingrix, the patient experienced injection site erythema (Verbatim: she had a red injection site that was hot), injection site warmth (Verbatim: she had a red injection site that was hot) and hot dry skin (Verbatim: Hot dry skin). The outcome of the injection site erythema and hot dry skin were resolved and the outcome of the injection site warmth was not reported. It was unknown if the reporter considered the injection site erythema, injection site warmth and hot dry skin to be related to Shingrix. It was unknown if the company considered the injection site erythema, injection site warmth and hot dry skin to be related to Shingrix. Linked case(s) involving the same patient: US2025114529 Additional Information: GSK Receipt Date: 05-Sep-2025 The patient reported that six or seven years ago she received the Shingrix series. In 2018, the patient had all the reported events. For tolerance of second dose, refer case US2025114529.; Sender's Comments: US-GSK-US2025114529:same reporter